High Tech Pharmaceuticals Co., Ltd. (106190) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for High Tech Pharmaceuticals Co., Ltd. (106190:KRX), powered by AI.

Current Price
₩13,810
P/E Ratio
13.0
Market Cap
148.8B
Sector
Healthcare
What is the High Tech Pharmaceuticals Co., Ltd. stock price forecast?

High Tech Pharmaceuticals Co., Ltd. is currently trading at ₩13,810. View real-time AI analysis on Alpha Lenz.

What is High Tech Pharmaceuticals Co., Ltd. insider trading activity?

View the latest insider trading data for High Tech Pharmaceuticals Co., Ltd. on Alpha Lenz.

What is High Tech Pharmaceuticals Co., Ltd.'s P/E ratio?

High Tech Pharmaceuticals Co., Ltd.'s P/E ratio is 13.0.

High Tech Pharmaceuticals Co., Ltd.

KRX · 106190
₩13,810-180(-1.29%)Market closedKRX regular session 09:00–15:30 KST
Ask about High Tech Pharmaceuticals Co., Ltd.'s future dividend policy...
Alpha Chat Insight

High Tech Pharmaceuticals Co., Ltd. trades at a P/E of 13.0 (undervalued) with solid ROE of 9.2%.

Ask for details

Company Overview

High Tech Pharmaceuticals Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, and manufacturing of a wide array of healthcare products. Its primary function is to advance the field of medicine through innovative drug therapies and medical solutions designed to address various health conditions. High Tech Pharmaceuticals actively participates in numerous sectors including oncology, cardiology, and neurology, among others. This diverse focus allows the company to impact a broad spectrum of health challenges. The organization is known for its state-of-the-art research facilities and commitment to quality, adhering to strict regulatory standards in its operations. In the financial market, High Tech Pharmaceuticals holds a significant position, reflecting its reputation and influence in advancing medical science and delivering pharmaceutical solutions globally. The company's efforts in pioneering new treatment modalities and its collaborations with healthcare providers highlight its continuous contribution to the dynamic landscape of healthcare innovations.

CEO김정수
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩148,758,090,270Market Cap
₩70,183,145,360Revenue
10.63MShares Out
0Employees

Margins

24.14%Gross
27.50%EBITDA
18.32%Operating
19.70%Pre-Tax
16.35%Net

Valuation

12.96P/E
1.14P/B
2.12EV/Sales
7.03EV/EBITDA
9.85P/FCF

Growth (CAGR)

-11.99%Rev 3Yr
-1.18%Rev 5Yr
37.67%Op Inc 3Yr
N/AOp Inc 5Yr
25.02%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

8.09%ROA
9.17%ROE
9.87%ROIC

Financial Health

₩13,076,153,300Cash & Cash Equivalents
₩-50,976,570Net Debt
9.97%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

High Tech Pharmaceuticals Co., Ltd. (ticker: 106190) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $148.8B.

The current price is ₩13,810 with a P/E ratio of 12.96x and P/B of 1.14x.

ROE is 9.17% and operating margin is 18.32%. Annual revenue is $70.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
High Tech Pharmaceuticals Co., Ltd. (106190) Stock Forecast 2026 ₩13,810 — Price, Financials & Analyst Targets | Alpha Lenz